Ironjustic
Thu, Jan-24-08, 17:17
J Clin Invest. 2007 Sep;117(9):2649-57. Links The iron
chelator deferasirox protects mice from mucormycosis through
iron starvation. Ibrahim AS, Gebermariam T, Fu Y, Lin L,
Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr,
Spellberg BJ. Division of Infectious Diseases, Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center,
Torrance, California 90502, USA. ibrahim@labiomed.org
Mucormycosis causes mortality in at least 50% of cases despite
current first-line therapies. Clinical and animal data
indicate that the presence of elevated available serum iron
predisposes the host to mucormycosis. Here we demonstrate that
deferasirox, an iron chelator recently approved for use in
humans by the US FDA, is a highly effective treatment for
mucormycosis. Deferasirox effectively chelated iron from
Rhizopus oryzae and demonstrated cidal activity in vitro
against 28 of 29 clinical isolates of Mucorales at
concentrations well below clinically achievable serum levels.
When administered to diabetic ketoacidotic or neutropenic mice
with mucormycosis, deferasirox significantly improved survival
and decreased tissue fungal burden, with an efficacy similar
to that of liposomal amphotericin B. Deferasirox treatment
also enhanced the host inflammatory response to mucormycosis.
Most importantly, deferasirox synergistically improved
survival and reduced tissue fungal burden when combined with
liposomal amphotericin B. These data support clinical
investigation of adjunctive deferasirox therapy to improve the
poor outcomes of mucormycosis with current therapy. As iron
availability is integral to the pathogenesis of other
infections
(e.g., tuberculosis, malaria), broader investigation of
deferasirox as an antiinfective treatment is warranted.
PMID: 17786247 [PubMed - indexed for MEDLINE] Copyright (c)
2004 Wiley Periodicals, Inc.
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
chelator deferasirox protects mice from mucormycosis through
iron starvation. Ibrahim AS, Gebermariam T, Fu Y, Lin L,
Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr,
Spellberg BJ. Division of Infectious Diseases, Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center,
Torrance, California 90502, USA. ibrahim@labiomed.org
Mucormycosis causes mortality in at least 50% of cases despite
current first-line therapies. Clinical and animal data
indicate that the presence of elevated available serum iron
predisposes the host to mucormycosis. Here we demonstrate that
deferasirox, an iron chelator recently approved for use in
humans by the US FDA, is a highly effective treatment for
mucormycosis. Deferasirox effectively chelated iron from
Rhizopus oryzae and demonstrated cidal activity in vitro
against 28 of 29 clinical isolates of Mucorales at
concentrations well below clinically achievable serum levels.
When administered to diabetic ketoacidotic or neutropenic mice
with mucormycosis, deferasirox significantly improved survival
and decreased tissue fungal burden, with an efficacy similar
to that of liposomal amphotericin B. Deferasirox treatment
also enhanced the host inflammatory response to mucormycosis.
Most importantly, deferasirox synergistically improved
survival and reduced tissue fungal burden when combined with
liposomal amphotericin B. These data support clinical
investigation of adjunctive deferasirox therapy to improve the
poor outcomes of mucormycosis with current therapy. As iron
availability is integral to the pathogenesis of other
infections
(e.g., tuberculosis, malaria), broader investigation of
deferasirox as an antiinfective treatment is warranted.
PMID: 17786247 [PubMed - indexed for MEDLINE] Copyright (c)
2004 Wiley Periodicals, Inc.
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk